Mutations such as the myeloid transcription factor, the chromatin-modifying gene, the cohesion complex gene, the spliceosome complex, and most importantly the TP53 mutations are seen in a higher proportion in AML secondary to MDS. This evidence concerns the gene TP53 and myelodysplastic syndrome.